This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Agios (AGIO) Files NDA to FDA for Rare Disease Drug Mitapivat
by Zacks Equity Research
Agios (AGIO) submits a new drug application to the FDA for its lead candidate, mitapivat, for treating adults with pyruvate kinase deficiency. Stock up.
Geron (GERN) Soars on Imetelstat Data for Myelofibrosis
by Zacks Equity Research
Geron (GERN) publishes data from the phase II IMbark study evaluating its lead pipeline candidate, imetelstat, for treating relapsed/refractory myelofibrosis. Stock rises.
All You Need to Know About Trevena (TRVN) Rating Upgrade to Buy
by Zacks Equity Research
Trevena (TRVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Moving Average Crossover Alert: Trevena (TRVN)
by Zacks Equity Research
Trevena (TRVN) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
Trevena (TRVN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Trevena (TRVN) will provide updates on its newly launched drug and other pipeline products when it releases its third-quarter 2020 results.
Has Trevena (TRVN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (TRVN) Outperforming Other Medical Stocks This Year?
Trevena's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Trevena.
Is the Options Market Predicting a Spike in Trevena (TRVN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Trevena (TRVN) stock based on the movements in the options market lately.
Implied Volatility Surging for Trevena (TRVN) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Trevena (TRVN) stock based on the movements in the options market lately.
Trevena (TRVN) Looks Good: Stock Adds 8.8% in Session
by Zacks Equity Research
Trevena (TRVN) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Company News for June 3, 2020
by Zacks Equity Research
Companies in the news are: DCI, TENX, TRVN, BHTG
Is Trevena (TRVN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (TRVN) Outperforming Other Medical Stocks This Year?
Has Trevena, Inc. (TRVN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (TRVN) Outperforming Other Medical Stocks This Year?
Seattle Genetics Gets Early FDA Nod for Breast Cancer Drug
by Zacks Equity Research
The FDA grants accelerated nod to Seattle Genetics' (SGEN) Tukysa in combination with Herceptin and Xeloda to treat adults with advanced unresectable metastatic HER2-positive breast cancer.
Trevena Enters Oversold Territory
by Zacks Equity Research
Trevena has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Axsome's (AXSM) AXS-05 Fails to Meet Main Goal in TRD Study
by Zacks Equity Research
Axsome's (AXSM) AXS-05 meets key secondary endpoints in late-stage study for addressing patients with treatment resistant depression. However, the primary endpoint did not reach statistical significance.
Trevena's NDA for Pain Drug Oliceridine Gets FDA Acceptance
by Zacks Equity Research
FDA accepts Trevena's (TRVN) NDA for opioid analgesic, oliceridine, re-submitted last month. A decision is expected in August.
Trevena (TRVN) Resubmits NDA for Pain Drug Oliceridine to FDA
by Zacks Equity Research
Trevena (TRVN) resubmits the NDA to the FDA for IV oliceridine for the management of moderate-to-severe acute pain.
FDA Grants Priority Review to Global Blood's SCD Candidate
by Zacks Equity Research
The FDA accepts Global Blood's (GBT) new drug application for voxelotor under priority review to treat sickle cell disease. A decision is expected on Feb 26, 2020.
Trevena Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Trevena has been struggling lately, but the selling pressure may be coming to an end soon.
Emergent's Vaccine Portfolio Aids Growth Amid Competition
by Zacks Equity Research
Emergent's (EBS) vaccine portfolio holds potential with the newly-acquired Narcan nasal spray performing well in the first half of 2019. Stiff competition is a lingering concern.
Trevena (TRVN) to Post Q1 Earnings: What Awaits the Stock?
by Zacks Equity Research
During Trevena's (TRVN) first-quarter 2019 conference call, investor focus will be on the company's progress to support its development of the pain therapy ??? oliceridine injection.
Mallinckrodt (MNK) Completes Enrollment in Skin Tissue Study
by Zacks Equity Research
Mallinckrodt (MNK) ends enrollment in the phase III study on StrataGraft, a regenerative skin tissue used in patients with thermal burns.
Trevena (TRVN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Trevena (TRVN) closed at $1.70 in the latest trading session, marking a +1.19% move from the prior day.
Will Trevena Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Trevena.